Another class action lawsuit hits Abiomed; Mobile app use jumps with device monitoring;

 @FierceMedDev: NanoString draws $15.3M Series E for cancer diagnostics test launch. Story | Follow @FierceMedDev

@MarkHFierce: SCOTUS will consider whether human genes can be patented. The case has profound implications for the future of Dx. More | Follow @MarkHFierce

 @DamianFierce: A European nonprofit says Big Pharma needs to keep a closer eye on its CRO partners, and ACRO cries foul. Story | Follow @DamianFierce

> Abiomed ($ABMD) faces another class action lawsuit connected to a U.S. Attorney's Office investigation into the marketing and labeling of its Impella 2.5 heart pump. Item

> Medical devices of the future will be shaped by a demand for more flexibility, cleanability and end-of-the-line robotics, according to a new industry report. Story

> In light of increased skin cancers and new use restrictions around the world, the FDA is continuing to reevaluate how it regulates tanning beds, which are currently ranked as Class I devices--the safest designation with minimal oversight. Story

> Physicians' and clinicians' reliance on mobile apps to collect bedside health data, medical-device monitoring data or use the bar code reader on mobile devices has grown substantially over the past year, according to a new cell phone industry survey. Release

> CareFusion ($CFN) says it will beef up the capabilities of its Alaris smart infusion pumps by adding Cerner Millennium electronic health records technology--an initiative planned for Children's Hospitals and Clinics of Minnesota. Release

> Women would pursue more cancer screening if they knew they had dense breasts, which are considered high risk for breast cancer, according to a new survey. Story

Biotech News

 @FierceBiotech: From FierceBiotechIT.com: Database aims to speed discoveries for blood cancer treatments. Report | Follow @FierceBiotech

 @JohnCFierce: Another figure for "average" drug R&D costs--1.2B sterling--biotech efficient source of new drugs, via FT. More (sub. req.) | Follow @JohnCFierce

 @RyanMFierce: Say what? Reuters is making some noise about the neglected $4.6B market for hearing-loss drugs. Story | Follow @RyanMFierce

> GSK spotlights PhIII heart, cancer blockbuster hopefuls in late-stage R&D review. Article

> Merck ignores red flags and throws dice on PhII/III Alzheimer's gamble. News

Pharma News

@FiercePharma: ICYMI: Pfizer is cutting its US primary care sales force. $$ down in that group post-Lipitor--Dow Jones. News | Follow @FiercePharma

> Pfizer sharpens job-cutting ax for U.S. sales layoffs. News

> Bill suggests wholesale pricing to fight drug shortages. Story

Biotech IT News

> Stanford to rival Broad Institute with Big Data-focused genomics center. Report

> Study: Genomics, outsourcing fuel double-digit growth in bioinformatics. Article

> Social media, iPhone app aid efforts to crowdsource disease surveillance. News

> Why Big Data alone lacks the punch pharma needs. Story

CRO News

> Indian regulators want crackdown on unethical CROs. Report

> CROs lack oversight, report says; ACRO cries foul. Story

> AMRI shutters R&D site, moving jobs to Singapore. News

> Parexel partners with Taiwan hospital for drug development. More

Suggested Articles

Dexcom received a new European approval for its wearable continuous glucose monitor in pregnant women across Type 1, Type 2 and gestational diabetes.

Infectious disease blood tester Karius has raised $165 million led by SoftBank’s Vision Fund 2, the Japanese conglomerate’s sequel to its VC megafund.

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.